The thymosin alpha 1 vaccine study found higher levels of antibodies, proteins that recognize a virus, in some older men after a flu shot. It did not establish fewer flu infections or hospital stays. A better blood-test result is a narrower finding than a general boost to immunity.
What the thymosin alpha 1 vaccine study asked
Could adding thymosin alpha-1 help older men produce more antibodies after flu vaccination? That was the question Stefan Gravenstein and colleagues explored in their 1989 Journal of the American Geriatrics Society study.
Thymosin alpha-1 is a peptide, a short chain of protein building blocks. Its medicine name is thymalfasin; its discovery story explains the origins.
Who joined, and what they received
Researchers assigned 90 men aged 65–99 by chance to thymosin alpha-1 or placebo, a matching preparation without the peptide. The study was double-blind: neither participants nor the team knew the assignments. Blood samples from 85 men were usable for analysis.
These were older male veterans. Everyone received the 1986 Fluzone vaccine, which targeted three influenza viruses. Study injections began immediately afterward, according to FDA's later evaluation.
The dosage guide covers the trial regimen. A prescriber sets any individual dose.
What the blood tests measured
An antibody titer is a laboratory measure of antibody level. The study defined a response as a fourfold rise over three to six weeks after vaccination. Researchers used ELISA, a test that measures antibody binding.
Seroconversion means a new positive antibody result or a study-defined rise in levels.
An antibody rise is a surrogate outcome: a laboratory clue used in place of an illness outcome. WHO distinguishes substitute measurements from clinical outcomes. More antibody does not count how many people avoided flu.
At six weeks, antibody amounts were higher
The peptide group produced more antibody than the placebo group at six weeks, with P=0.023. A P value measures how compatible the data are with no treatment difference. It does not measure the percentage of infections prevented.
The published abstract locates the clearest difference in men aged 77 or older:
| Six-week comparison | Peptide plus vaccine | Placebo plus vaccine | Reported comparison |
|---|---|---|---|
| All ages combined | Higher antibody amount | Lower antibody amount | P=0.023 |
| Men aged 77 or older | Higher antibody amount | Lower antibody amount | P=0.039 |
| Men aged 65–76 | No observed difference between arms | No observed difference between arms | No difference reported |
These comparisons do not establish percentages protected from flu or reductions in hospital stays.
What was recorded about side effects?
The investigators reported no toxicity in either group. That means no toxic effects were observed in this small trial; it does not establish that every possible reaction was ruled out.
| Study group | Safety finding reported in the abstract |
|---|---|
| Thymosin alpha-1 | No toxicity observed |
| Placebo | No toxicity observed |
A small study can miss uncommon problems. It also cannot establish the safety of prolonged use or every preparation containing the same peptide.
What later studies and FDA's review added
Ershler and colleagues' 2007 trial summary, in Annals of the New York Academy of Sciences, described favorable vaccine-response findings in animals and people. The authors called for further research. It was a summary of the developing evidence, rather than a new confirmation of fewer infections.
A 2012 pilot in Vaccine by Carraro and colleagues studied people receiving hemodialysis, a treatment that filters blood when kidneys fail. It compared Focetria, a vaccine against H1N1, one type of flu virus, alone with two groups receiving the vaccine plus thymalfasin.
Its safety analysis included 99 people; its main antibody analysis included 94. Antibody measures favored both peptide groups on day 21. By day 42 the early advantage had reversed: on days 42, 84 and 168, FDA's review reports higher seroconversion, protective-level and average antibody results in the vaccine-only group. No adverse event, a medical problem recorded during a study, was attributed to either study treatment.
FDA's evaluation describes that pilot as randomized and open-label, meaning the assignments were known. It questions the durability of the antibody findings. For the older men's trial, FDA also flags small subgroups and a vaccine that predates today's preferred options for older adults. Neither study settles the question of added benefit with current flu vaccines.
How the finding gets stretched
The jump from “antibody levels rose after this vaccine” to “the immune system is stronger against everything” changes the question. It also changes the population: older men and people on dialysis cannot stand in for healthy adults of every age.
The broader benefits guide examines other conditions. The TESTS sepsis trial, which studied a life-threatening response to infection, asked a separate question about survival. Results in one setting cannot supply the missing answer in another.
As of October 1, 2026, the day this article was written, NCT06821100 lists a recruiting Houston Methodist study of thymalfasin before COVID boosters. Its record, updated July 16, 2026, plans 75 adults aged 65 or older. This phase 1 study, an early trial focused mainly on safety, has no posted results. A recruiting study is work underway, not evidence that treatment helps.
Overseas authorization and today's flu-vaccine choices
As of October 1, 2026, the day this article was written, Italy's Zadaxin leaflet, made available February 26, 2026, lists use alongside flu vaccination in people with weakened immunity. Singapore's formulary entry, marked “Last updated 16 September 2026,” instead lists specified hepatitis B and C uses, both viral liver infections. These records concern particular products and uses; their document dates are not new authorization dates. The peptide overview covers that wider record.
As of October 1, 2026, the day this article was written, CDC's flu-vaccine page, updated September 1, 2026, prefers three options for adults 65 and older: Fluzone High-Dose, Flublok and Fluad. If none is available, CDC recommends another age-appropriate flu vaccine. The peptide studies do not replace that vaccination recommendation.
What this means for a compounded prescription
As of October 1, 2026, the day this article was written, thymosin alpha-1 has no FDA-approved U.S. product. FDA's evaluation documents that history, and its hepatitis B record still lists no approval. The U.S. regulatory record explains the separate review.
Thymosin alpha-1 prescribed through Promise is dispensed as a compounded medication, prepared by a licensed pharmacy for an individual prescription. It is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA does not review compounded medicines for safety, effectiveness or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor. The vaccine studies do not establish that a compounded preparation matches the study medication's performance.
What belongs in the provider conversation?
The useful question is whether the intended goal resembles the question tested. A review also considers allergies, transplant history and medicines affecting immunity. Autoimmune disease, where immunity attacks the body's own tissues, also matters. Pregnancy and breastfeeding are part of that review too.
At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies. If a prescription is appropriate, the provider sets the plan and follow-up. An old antibody finding supplies context for that conversation; it cannot decide it.
